Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more
Pfizer Inc (PFE) - Net Assets
Latest net assets as of September 2025: $93.10 Billion USD
Based on the latest financial reports, Pfizer Inc (PFE) has net assets worth $93.10 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($208.73 Billion) and total liabilities ($115.64 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $93.10 Billion |
| % of Total Assets | 44.6% |
| Annual Growth Rate | 9.13% |
| 5-Year Change | 39.42% |
| 10-Year Change | 36.15% |
| Growth Volatility | 74.68 |
Pfizer Inc - Net Assets Trend (1985–2024)
This chart illustrates how Pfizer Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pfizer Inc (1985–2024)
The table below shows the annual net assets of Pfizer Inc from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $88.50 Billion | -0.89% |
| 2023-12-31 | $89.29 Billion | -6.91% |
| 2022-12-31 | $95.92 Billion | +23.82% |
| 2021-12-31 | $77.46 Billion | +22.04% |
| 2020-12-31 | $63.47 Billion | +0.04% |
| 2019-12-31 | $63.45 Billion | -0.49% |
| 2018-12-31 | $63.76 Billion | -11.02% |
| 2017-12-31 | $71.66 Billion | +19.75% |
| 2016-12-31 | $59.84 Billion | -7.94% |
| 2015-12-31 | $65.00 Billion | -9.25% |
| 2014-12-31 | $71.62 Billion | -6.52% |
| 2013-12-31 | $76.62 Billion | -6.19% |
| 2012-12-31 | $81.68 Billion | -1.14% |
| 2011-12-31 | $82.62 Billion | -6.39% |
| 2010-12-31 | $88.27 Billion | -2.41% |
| 2009-12-31 | $90.45 Billion | +56.64% |
| 2008-12-31 | $57.74 Billion | -11.34% |
| 2007-12-31 | $65.12 Billion | -7.92% |
| 2006-12-31 | $70.72 Billion | +6.58% |
| 2005-12-31 | $66.36 Billion | -3.67% |
| 2004-12-31 | $68.88 Billion | +5.36% |
| 2003-12-31 | $65.38 Billion | +227.70% |
| 2002-12-31 | $19.95 Billion | +9.06% |
| 2001-12-31 | $18.29 Billion | +13.79% |
| 2000-12-31 | $16.08 Billion | +410.03% |
| 1999-12-31 | $3.15 Billion | -64.22% |
| 1998-12-31 | $8.81 Billion | +6.43% |
| 1997-12-31 | $8.28 Billion | +18.19% |
| 1996-12-31 | $7.00 Billion | +26.13% |
| 1995-12-31 | $5.55 Billion | +27.29% |
| 1994-12-31 | $4.36 Billion | +11.73% |
| 1993-12-31 | $3.90 Billion | -17.85% |
| 1992-12-31 | $4.75 Billion | -6.07% |
| 1991-12-31 | $5.06 Billion | -1.17% |
| 1990-12-31 | $5.12 Billion | +12.30% |
| 1989-12-31 | $4.56 Billion | +6.02% |
| 1988-12-31 | $4.30 Billion | +10.78% |
| 1987-12-31 | $3.88 Billion | +13.68% |
| 1986-12-31 | $3.42 Billion | +16.67% |
| 1985-12-31 | $2.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pfizer Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $92.80 Billion | 99.68% |
| Other Components | $295.00 Million | 0.32% |
| Total Equity | $93.10 Billion | 100.00% |
Pfizer Inc Competitors by Market Cap
The table below lists competitors of Pfizer Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toyota Motor Corp
PINK:TOYOF
|
$156.23 Billion |
|
Toronto Dominion Bank
NYSE:TD
|
$156.30 Billion |
|
Charles Schwab Corp
NYSE:SCHW
|
$157.13 Billion |
|
China Merchants Bank Co Ltd
PINK:CIHKY
|
$157.57 Billion |
|
Siemens AG Class N
PINK:SMAWF
|
$155.24 Billion |
|
Deere & Company
NYSE:DE
|
$154.81 Billion |
|
Primary Health Prop PLC
JSE:PHP
|
$153.12 Billion |
|
Softbank Group Corp.
PINK:SFTBF
|
$150.75 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pfizer Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 88,203,000,000 to 93,096,000,000, a change of 4,893,000,000 (5.5%).
- Net income of 7,770,000,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 100,643,000,000.
- Other factors decreased equity by 103,520,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.77 Billion | +8.35% |
| Other Comprehensive Income | $100.64 Billion | +108.11% |
| Other Changes | $-103.52 Billion | -111.2% |
| Total Change | $- | 5.55% |
Book Value vs Market Value Analysis
This analysis compares Pfizer Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 38.83x to 1.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.71 | $27.45 | x |
| 1986-12-31 | $0.83 | $27.45 | x |
| 1987-12-31 | $0.96 | $27.45 | x |
| 1988-12-31 | $1.03 | $27.45 | x |
| 1989-12-31 | $1.07 | $27.45 | x |
| 1990-12-31 | $1.33 | $27.45 | x |
| 1991-12-31 | $1.25 | $27.45 | x |
| 1992-12-31 | $1.16 | $27.45 | x |
| 1993-12-31 | $1.00 | $27.45 | x |
| 1994-12-31 | $1.16 | $27.45 | x |
| 1995-12-31 | $1.46 | $27.45 | x |
| 1996-12-31 | $1.80 | $27.45 | x |
| 1997-12-31 | $2.01 | $27.45 | x |
| 1998-12-31 | $2.24 | $27.45 | x |
| 1999-12-31 | $1.41 | $27.45 | x |
| 2000-12-31 | $2.52 | $27.45 | x |
| 2001-12-31 | $2.88 | $27.45 | x |
| 2002-12-31 | $3.20 | $27.45 | x |
| 2003-12-31 | $8.97 | $27.45 | x |
| 2004-12-31 | $8.97 | $27.45 | x |
| 2005-12-31 | $8.86 | $27.45 | x |
| 2006-12-31 | $9.81 | $27.45 | x |
| 2007-12-31 | $9.37 | $27.45 | x |
| 2008-12-31 | $8.53 | $27.45 | x |
| 2009-12-31 | $12.78 | $27.45 | x |
| 2010-12-31 | $10.88 | $27.45 | x |
| 2011-12-31 | $10.44 | $27.45 | x |
| 2012-12-31 | $10.82 | $27.45 | x |
| 2013-12-31 | $11.07 | $27.45 | x |
| 2014-12-31 | $55.50 | $27.45 | x |
| 2015-12-31 | $51.72 | $27.45 | x |
| 2016-12-31 | $48.34 | $27.45 | x |
| 2017-12-31 | $58.85 | $27.45 | x |
| 2018-12-31 | $10.61 | $27.45 | x |
| 2019-12-31 | $11.13 | $27.45 | x |
| 2020-12-31 | $11.23 | $27.45 | x |
| 2021-12-31 | $13.53 | $27.45 | x |
| 2022-12-31 | $16.69 | $27.45 | x |
| 2023-12-31 | $15.59 | $27.45 | x |
| 2024-12-31 | $15.47 | $27.45 | x |
| 2025-12-31 | $16.37 | $27.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pfizer Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.35%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.42%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (8.35%) is below the historical average (19.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 19.80% | 14.40% | 0.90x | 1.52x | $286.97 Million |
| 1986 | 19.32% | 14.75% | 0.87x | 1.51x | $318.47 Million |
| 1987 | 17.78% | 14.03% | 0.71x | 1.78x | $301.96 Million |
| 1988 | 18.40% | 14.69% | 0.71x | 1.78x | $361.19 Million |
| 1989 | 15.02% | 12.01% | 0.68x | 1.84x | $227.52 Million |
| 1990 | 15.73% | 12.51% | 0.71x | 1.78x | $292.00 Million |
| 1991 | 14.37% | 10.39% | 0.72x | 1.92x | $219.47 Million |
| 1992 | 17.19% | 11.22% | 0.75x | 2.03x | $339.04 Million |
| 1993 | 17.01% | 8.79% | 0.80x | 2.41x | $270.95 Million |
| 1994 | 30.03% | 15.68% | 0.75x | 2.57x | $866.01 Million |
| 1995 | 28.56% | 15.70% | 0.79x | 2.31x | $1.02 Billion |
| 1996 | 27.74% | 17.06% | 0.77x | 2.11x | $1.23 Billion |
| 1997 | 27.90% | 17.70% | 0.82x | 1.93x | $1.42 Billion |
| 1998 | 38.04% | 24.74% | 0.74x | 2.08x | $2.47 Billion |
| 1999 | 35.77% | 19.62% | 0.79x | 2.32x | $2.29 Billion |
| 2000 | 23.18% | 12.60% | 0.88x | 2.08x | $2.12 Billion |
| 2001 | 42.57% | 24.14% | 0.82x | 2.14x | $5.96 Billion |
| 2002 | 45.74% | 28.19% | 0.70x | 2.32x | $7.13 Billion |
| 2003 | 5.98% | 8.65% | 0.39x | 1.79x | $-2.63 Billion |
| 2004 | 16.60% | 21.58% | 0.42x | 1.81x | $4.50 Billion |
| 2005 | 11.60% | 16.05% | 0.40x | 1.79x | $1.05 Billion |
| 2006 | 15.45% | 22.79% | 0.42x | 1.61x | $3.89 Billion |
| 2007 | 12.63% | 16.95% | 0.42x | 1.77x | $1.71 Billion |
| 2008 | 13.94% | 16.61% | 0.43x | 1.93x | $2.27 Billion |
| 2009 | 9.59% | 17.27% | 0.23x | 2.37x | $-366.40 Million |
| 2010 | 9.42% | 12.33% | 0.34x | 2.22x | $-513.30 Million |
| 2011 | 10.59% | 14.26% | 0.32x | 2.29x | $486.00 Million |
| 2012 | 12.04% | 17.91% | 0.29x | 2.29x | $1.66 Billion |
| 2013 | 15.27% | 22.58% | 0.30x | 2.26x | $4.02 Billion |
| 2014 | 12.73% | 18.30% | 0.29x | 2.37x | $1.95 Billion |
| 2015 | 10.76% | 14.26% | 0.29x | 2.59x | $494.00 Million |
| 2016 | 12.12% | 13.66% | 0.31x | 2.88x | $1.26 Billion |
| 2017 | 29.88% | 40.55% | 0.31x | 2.41x | $14.17 Billion |
| 2018 | 17.59% | 20.79% | 0.34x | 2.51x | $4.81 Billion |
| 2019 | 25.77% | 39.52% | 0.25x | 2.65x | $9.96 Billion |
| 2020 | 14.48% | 21.99% | 0.27x | 2.44x | $2.84 Billion |
| 2021 | 28.69% | 27.25% | 0.45x | 2.35x | $14.43 Billion |
| 2022 | 32.79% | 31.26% | 0.51x | 2.06x | $21.80 Billion |
| 2023 | 2.40% | 3.58% | 0.26x | 2.54x | $-6.77 Billion |
| 2024 | 9.09% | 12.60% | 0.30x | 2.42x | $-800.30 Million |
| 2025 | 8.35% | 12.42% | 0.00x | 0.00x | $-1.54 Billion |
Industry Comparison
This section compares Pfizer Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pfizer Inc (PFE) | $93.10 Billion | 19.80% | 1.24x | $155.81 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |